A single-agent LDN protocol used off-label for chronic pain, inflammation, and fatigue conditions.
Low-dose naltrexone (typically 1.5–4.5 mg) is an off-label use of an opioid antagonist that, at these micro-doses, appears to modulate inflammation and glial activity — studied in chronic pain, fibromyalgia, and fatigue conditions. It's a single-agent 'stack' because it's usually run alone and titrated carefully.
LDN is prescription naltrexone repurposed; the low-dose protocol is off-label and should be physician-supervised. The evidence is promising but still emerging for most indications.
| Compound | Role | Dose | Frequency |
|---|---|---|---|
| Naltrexone Off-label low-dose; physician-supervised. | Primary | 1.5–4.5 mg/day (LDN), titrated from low | Once daily at bedtime |